Over 15 years of global business experience where he has negotiated several strategic alliances and licensing deals, established joint ventures and assisted in private financings to support product development.

Dr. Babaei holds a PhD and an executive MBA, both from the University of Toronto. He has authored over 50 publications including research papers, conference presentations and patents. He currently serves as a member of Board of Director

Brings to AbCelex extensive experience in molecular biology and antibody design and engineering. At AbCelex, Dr. Riazi is responsible for all scientific operations of the Company including establishing and managing various R&D collaborations and strategic partnerships. Prior to joining AbCelex, Dr. Riazi was heading a team of scientists engaged in elucidating molecular mechanisms of cardiovascular disease at the Hospital for Sick Children.

- Over 20 years of experience with increasing responsibility with two multinational pharmaceuticals including COO of Naturagen Health Solutions, within Elanco, a division of Eli Lilly and Company (NYSE:LLY).
- CEO of Chemaphor, involved in development of pharmaceuticals and veterinary natural health products.
- Holds a veterinary degree with advanced training in infectious diseases and immunology.

With more than 20 years industry experience, Mr. Mandl is a seasoned technology and business leader. He has a proven record driving innovation, executing on strategic plans and delivering results. With both large and small company experience, Mr. Mandl was a key contributor to several start-ups including a successful IPO at Genesis Microchip Inc. His diverse background includes sales, marketing, finance, product management, contracts, IP licens